NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout

    India
    Business
    World
    Politics
    Sports
    Technology
    Entertainment
    Auto
    Lifestyle
    Inspirational
    Career
    Bengaluru
    Delhi
    Mumbai

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
    Home / News / Technology News / India to play crucial role in COVID-19 vaccine process
    Next Article
    India to play crucial role in COVID-19 vaccine process

    India to play crucial role in COVID-19 vaccine process

    By Siddhant Pandey
    Oct 20, 2020
    04:34 pm

    What's the story

    As the world's largest vaccine manufacturer, India will play a major role in the vaccination efforts for COVID-19.

    The nation has been involved in the development and manufacturing of vaccines and will possibly also be involved in distribution once a vaccine is ready.

    Notably, India is among the worst-hit nations, with nearly 7.6 million coronavirus infections and over 1.15 lakh deaths.

    AstraZeneca

    Serum Institute to produce one billion doses

    The Pune-based Serum Institute of India (SII)—the world's largest vaccine manufacturer—has entered a deal to produce one billion doses of the vaccine developed by Oxford University and AstraZeneca.

    The SII has already initiated the production of two million vaccine samples.

    The institute has said it hopes the vaccine to be ready by December and expects licensing for distribution in India by March.

    Trials

    Off-the-record trial data very promising: SII CEO

    The SII is conducting Phase III human clinical trials across India.

    SII CEO Adar Poonawalla said, "A lot of the data that I have seen off-the-record in a lot of these vaccines is very promising and more than three to four vaccines will be successful very soon in the next year."

    Separately, the institute has also started trials for an intranasal vaccine.

    Other vaccines

    Other pharma firms have also entered vaccine deals

    Meanwhile, Indian pharmaceutical firm Biological E has also struck a deal to produce 500 million doses of Johnson and Johnson's vaccine.

    Hyderabad-based Bharat Biotech has a deal to manufacture one billion doses of Washington University's intranasal vaccine.

    Further, Dr. Reddy's has entered a deal to produce 100 million doses of Russia's Sputnik vaccine.

    India is also producing at least a dozen indigenous vaccines.

    Prioritization

    '50% of what we manufacture will be kept for India'

    According to The Guardian, India's central role in vaccine development puts the global south at an advantage.

    Poonawalla has said, "50% of whatever quantity we manufacture will be kept for India and the remaining will go to low- and middle-income countries."

    The company would also halt the production of other vaccines—such as measles, mumps, rubella, and Hepatitis B—intended for the United States and Europe.

    Prioritization

    Biological E made no plans to reserve vaccine doses

    However, Biological E CEO Mahima Datla said the company is committed to the COVAX vaccine alliance, which pushes for equal procurement and distribution.

    "We have never made trade-off decisions between the vaccine needs of India and global organizations such as UNICEF," said Datla, adding that there might be a demand-supply gap that might warrant reservation of the vaccine.

    Challenges

    Mass immunization drive to be challenging in India

    Ironically though, in India, a nationwide immunization effort is set to hit several roadblocks.

    The nation of 1.3 billion people has an effective mechanism for immunizing pregnant women and babies, however, there is no such mechanism for the rest of the population.

    India also lacks adequate cold-chain facilities, which is a requirement for vaccines that need to be stored at up to -70°C.

    Challenges

    Financial concerns another hurdle in vaccination efforts

    To note, the SII will likely price the vaccine at about $5. The government plans to immunize 250 million people by July 2021, which would require $1.25 billion.

    Microbiology professor Gagandeep Kang said the main worry is the scale and tracking. "How do you know who got the vaccine and who didn't—and the fact that the storage conditions needed are still an unknown."

    Quote

    Kang warned about anti-vaccination movement

    Kang also warned about anti-vaccination conspiracies taking root in rural India. Kang said, "I worry that the longer it takes for a COVID-19 vaccination program to roll out in India, the more anti-vaccine conspiracies theories and resistance we will have to deal with."

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Latest
    Vaccine
    Oxford University
    COVID-19
    Serum Institute of India

    Latest

    'Sirens,' 'Nine Perfect Strangers': Your OTT watchlist this week Nicole Kidman
    'Fear Street: Prom Queen': Cast, plot, release details OTT releases
    IPL 2025, LSG vs SRH: How the Impact Players fared  Sunrisers Hyderabad (SRH)
    Microsoft employee disrupts Nadella's keynote: What's behind the protest? Satya Nadella

    Vaccine

    SII gets nod for Oxford COVID vaccine phase 2/3 trials Oxford
    Coronavirus: Who will be first in line for the vaccine? World Health Organization
    COVAXIN will cost less than water bottle: Bharat Biotech MD COVID-19
    Serum Institute's COVID-19 vaccines will come at $3 per dose Oxford

    Oxford University

    Malala visits Pakistan for first time since she was shot Pakistan News
    Pakistan divided over Malala Yousafzai visiting homeland Pakistan News
    Ancient finger bone pushes back human migration from Africa Saudi Arabia
    Oxford University crash course for two Indian teaching Olympiad winners Mumbai

    COVID-19

    Manish Sisodia, admitted to hospital with COVID-19, diagnosed with dengue Manish Sisodia
    Singer SP Balasubrahmanyam passes away due to COVID-19 complications SP Balasubrahmanyam
    Coronavirus cases and hospitalization up again in France Paris
    Coronavirus: Global deaths near one million; a million more 'likely' World Health Organization

    Serum Institute of India

    Amid coronavirus crisis, this Indian business tycoon is growing richer Mukesh Ambani
    India will start COVID-19 vaccine production next month: Details here Oxford
    COVID-19 vaccine: What are the latest updates? Oxford
    COVID-19 vaccine: What are the latest updates? Oxford
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2025